Xiaobo Feng Verified

Pharmaceutical and Biotechnology Regulatory Compliance in Wuhan

Xiaobo Feng advises pharmaceutical companies, biotech firms, medical institutions and contract manufacturers on regulatory compliance, drug patents and commercial contracting from Wuhan.

Mr. Feng practices at a Wuhan law firm. He was admitted in 2012 and has about fourteen years of professional experience, working in English and Mandarin with Hubei Bar Association credentials on file.

Drug product lifecycle work spans research, registration, production, distribution and use. He supports compliance system design, governance, commercial contracts and dispute prevention for pharmaceutical and healthcare entities.

Drug Patent Linkage and Challenge Watch

Linkage is a calendar sport. Originators who only check the patent office when someone emails miss the declaration window that forces strategy under regulatory review pressure.

He builds minimum watch stacks: listed patents for each franchise product kept accurate and commercially relevant, competitive filing intelligence tied to declaration types, pre-built infringement experiment plans and validity defence outlines.

Settlement playbooks are designed to survive anti-monopoly and tender optics. A challenge may be the first signal of a design-around; litigation, patent prosecution and licence valuation are aligned on the same expiry model.

Commercial Contracting and Disputes

When products are detained, delisted or disputed under supply contracts, he builds enforcement and settlement strategies with bilingual summaries for overseas manufacturers.

Contract manufacturing and supply arrangements need allocation of liability for batch failure, technology transfer completeness, liability caps and carve-outs for gross negligence and regulatory false statements.

When a batch fails, three clocks start: disposition of material, root-cause CAPA and the commercial launch calendar. He structures joint investigation plans under counsel when values are high.

How to Engage

Provide product type, patent status, supply contract structure and any dispute or regulatory notice already received. Scope is confirmed in writing through this profile's inquiry channel.